Clearbridge Investments LLC Sells 3,515 Shares of DexCom, Inc. (NASDAQ:DXCM)

Clearbridge Investments LLC trimmed its holdings in DexCom, Inc. (NASDAQ:DXCM) by 9.0% in the 2nd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 35,443 shares of the medical device company’s stock after selling 3,515 shares during the quarter. Clearbridge Investments LLC’s holdings in DexCom were worth $4,019,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of DXCM. Migdal Insurance & Financial Holdings Ltd. bought a new stake in DexCom in the 2nd quarter valued at $25,000. Sachetta LLC raised its position in shares of DexCom by 255.2% during the second quarter. Sachetta LLC now owns 238 shares of the medical device company’s stock valued at $27,000 after buying an additional 171 shares during the last quarter. Crewe Advisors LLC acquired a new position in shares of DexCom during the first quarter valued at about $29,000. Riverview Trust Co bought a new stake in shares of DexCom in the first quarter valued at about $32,000. Finally, DT Investment Partners LLC grew its position in DexCom by 492.2% during the second quarter. DT Investment Partners LLC now owns 379 shares of the medical device company’s stock worth $43,000 after buying an additional 315 shares in the last quarter. 97.75% of the stock is owned by institutional investors.

DexCom Stock Up 3.7 %

Shares of DXCM opened at $68.11 on Friday. The company has a market capitalization of $27.09 billion, a P/E ratio of 43.94, a PEG ratio of 2.16 and a beta of 1.18. DexCom, Inc. has a one year low of $62.34 and a one year high of $142.00. The business’s 50 day simple moving average is $70.19 and its 200-day simple moving average is $104.95. The company has a debt-to-equity ratio of 1.00, a current ratio of 2.82 and a quick ratio of 2.48.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, July 25th. The medical device company reported $0.43 EPS for the quarter, topping analysts’ consensus estimates of $0.39 by $0.04. DexCom had a return on equity of 31.41% and a net margin of 16.95%. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $1.04 billion. During the same quarter in the previous year, the firm earned $0.34 earnings per share. The business’s revenue was up 15.3% on a year-over-year basis. As a group, sell-side analysts predict that DexCom, Inc. will post 1.69 EPS for the current fiscal year.

Analysts Set New Price Targets

Several research firms have commented on DXCM. BTIG Research cut their price target on DexCom from $156.00 to $120.00 and set a “buy” rating for the company in a report on Friday, July 26th. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research note on Wednesday. UBS Group decreased their price target on shares of DexCom from $163.00 to $95.00 and set a “buy” rating on the stock in a research note on Friday, July 26th. Barclays lowered their price target on shares of DexCom from $138.00 to $113.00 and set an “equal weight” rating on the stock in a report on Monday, July 29th. Finally, Stifel Nicolaus raised their price objective on shares of DexCom from $90.00 to $100.00 and gave the stock a “buy” rating in a report on Friday, August 23rd. Seven equities research analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $112.25.

Insider Buying and Selling

In other DexCom news, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the completion of the sale, the executive vice president now owns 66,249 shares in the company, valued at approximately $4,607,617.95. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. In other news, EVP Michael Jon Brown sold 652 shares of the firm’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $69.55, for a total value of $45,346.60. Following the transaction, the executive vice president now owns 66,249 shares of the company’s stock, valued at approximately $4,607,617.95. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Sadie Stern sold 426 shares of the business’s stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $69.15, for a total transaction of $29,457.90. Following the sale, the executive vice president now directly owns 75,451 shares of the company’s stock, valued at approximately $5,217,436.65. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,824 shares of company stock worth $126,390 in the last 90 days. Corporate insiders own 0.30% of the company’s stock.

DexCom Profile

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.